Mark Parrish Biography and Net Worth

Director of Omnicell

Mark Parrish has served as a Director of Omnicell since January 2013. Mr. Parrish serves as the President and CEO of the International Federation of Pharmaceutical Wholesalers. He also serves as a Senior Advisor at Frazier Healthcare Ventures and serves on the Board of Comprehensive Pharmaceutical Services, a Frazier-sponsored Company. His previous positions include CEO of TridentUSA Health Services; Chief Executive Officer for Healthcare Supply Chain Services of Cardinal Health Inc.; Chief Executive Officer and Director of Pharmaceutical Distribution and Provider Services of Cardinal Health Inc.; and President and Chief Operating Officer of Supply Chain Services of Cardinal Health Inc. Prior to that, Mr. Parrish held several leadership positions in Cardinal Health’s pharmaceutical distribution and pharmacy-franchising units. Mr. Parrish is Lead Director and Vice Chairman at Viatris Corporation (VTRS). He is a graduate of the University of California, Berkeley.

What is Mark W. Parrish's net worth?: The estimated net worth of Mark W. Parrish is at least $1.93 million as of December 10th, 2024. Mr. Parrish owns 58,427 shares of Omnicell stock worth more than $1,928,091 as of March 14th. This net worth evaluation does not reflect any other assets that Mr. Parrish may own. Learn More about Mark W. Parrish's net worth.
How do I contact Mark W. Parrish?: The corporate mailing address for Mr. Parrish and other Omnicell executives is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. Omnicell can also be reached via phone at (877) 415-9990 and via email at ir@omnicell.com. Learn More on Mark W. Parrish's contact information.
Has Mark W. Parrish been buying or selling shares of Omnicell?: Mark W. Parrish has not been actively trading shares of Omnicell in the last ninety days. Most recently, Mark W. Parrish sold 12,000 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a transaction totalling $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares of the company's stock, valued at $2,763,597.10. Learn More on Mark W. Parrish's trading history.
Who are Omnicell's active insiders?: Omnicell's insider roster includes Joanne Bauer (Director), Dan Johnston (EVP), James Judson (Director), Peter Kuipers (CFO), Randall Lipps (CEO), Christine Mellon (EVP), Mark Parrish (Director), Scott Seidelmann (EVP), Robin Seim (Director), and Joseph Spears (CAO). Learn More on Omnicell's active insiders.
Are insiders buying or selling shares of Omnicell?: During the last year, insiders at the sold shares 1 times. They sold a total of 12,000 shares worth more than $567,600.00. The most recent insider tranaction occured on December, 10th when Director Mark W Parrish sold 12,000 shares worth more than $567,600.00. Insiders at Omnicell own 2.6% of the company. Learn More about insider trades at Omnicell.
Information on this page was last updated on 12/10/2024.

Mark W. Parrish Insider Trading History at Omnicell

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/10/2024	Sell	12,000	$47.30	$567,600.00	58,427

Mark W. Parrish Buying and Selling Activity at Omnicell

Omnicell Company Overview

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Today's Range

Now: $33.00

$32.40

$33.47

50 Day Range

MA: $40.71

$32.28

$45.31

2 Week Range

Now: $33.00

$25.12

$55.75

Volume

828,624 shs

Average Volume

496,526 shs

Market Capitalization

$1.54 billion

P/E Ratio

122.23

Dividend Yield

N/A

Beta

0.85